An interventional study of Nocturnal polysomnography (NPSG) and Lumbar Puncture (LP) in Alzheimer Disease, sponsored by NYU Langone Health. Completed at 2 sites in United States. Open to participants aged 55 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Alzheimer Disease by NYU Langone Health — 2 open to participants now, 4 under way, none of them phase 3. Alzheimer Disease · NYU Langone Health.
Among the 22 studies in Alzheimer Disease by NYU Langone Health, this one is the 8th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2020, is one of 8 with no phase, and was the 17th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →2 of the 22 studies in Alzheimer Disease by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 60–85
NYU Langone Health · Sites in United States
Ages 60+
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 34 across the 15 interventional studies, 81 across the 7 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
4 of the studies in Alzheimer Disease by NYU Langone Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05606341NYU Langone HealthInnate Immunity Stimulation Via TLR9 in Early AD | 2026-11 |
| NCT03278119NYU Langone HealthSleep Aging and Risk for Alzheimer's 2.0 | 2026-12-25 |
| NCT05004987NYU Langone HealthAβ Dynamics in LLMD | 2026-12-31 |
| NCT06079203NYU Langone HealthED-LEAD: Emergency Departments Leading the Transformation of Alzheimer's and Dementia Care | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Alzheimer Disease by NYU Langone Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed since midlife. We have previously demonstrated functional vulnerability of the LC to aging and stress, as well as an association between higher cerebrospinal fluid (CSF) tau and impaired sleep phenomena influenced by the LC. We now aim to test whether LC dysfunction can be measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects sleep architecture and attention. We will test this hypothesis in 30 cognitively normal older adults by performing a full clinical evaluation, one night of polysomnography, a lumbar puncture to obtain cerebrospinal fluid, [11C]MRB PET-MR, and attention testing. This study has the potential to identify a new mechanism by which tau pathology contributes to sleep and attention dysfunction and may provide a new therapeutic target for AD prevention.
The purpose of this study is three-fold: to test whether lower NET availability in the LC is associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second, reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Nocturnal polysomnography (NPSG) · Procedure: Lumbar Puncture (LP) · Other: PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB) · Behavioral: Psychomotor Vigilance Task (PVT)
Nocturnal polysomnography (NPSG) to measure REM sleep and sleep spindles characteristics.
Lumbar puncture (LP) to measure CSF P-Tau, T-Tau and Aβ42/40 ratio.
PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-\[11C\]O-methylreboxetine (\[11C\]MRB) to measure NET availability.
Psychomotor vigilance task (PVT) and the OddBall to measure test taskattention performance.
Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values
Time frame: Visit 4 (1-4 weeks after LP that occurred on day 14)
Total Rapid Eye Movement (REM) Duration (Min)
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Time Spent in REM Sleep
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Less Than 5 Minutes
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Percentage of Correct Responses on the Picture Test
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density)
N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Mean Psychomotor Vigilance Test (PVT) Reaction Time
PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts.
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Picture Test Response Time
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.
Time frame: Visit 3 (1-4 weeks after Visit 2 which occurred on day 9)
Levels of Hyperphosphorylated Tau (P-Tau)
Levels will be derived from the plasma and reported in pg/mL
Time frame: Visit 4 (1-4 weeks after LP that occurred on day 14)
| Milestone | Cognitively Normal (CN) Older Adults |
|---|---|
| Started | 34 |
| Completed | 26 |
| Not completed | 8 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Met pre-specified exclusion criteria | 1 |
| Mean Standardized Uptake Value Ratio | Cognitively Normal (CN) Older Adults |
|---|---|
| Methylreboxetine (MRB)-LC Mean Standardized Uptake Value Ratio (SUVR) Values | 0.95 ± 0.52 |
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.
| Minutes | Cognitively Normal (CN) Older Adults |
|---|---|
| Total Rapid Eye Movement (REM) Duration (Min) | 74.75 ± 38.7 |
REM sleep is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.
| Percentage of total sleep time | Cognitively Normal (CN) Older Adults |
|---|---|
| Percentage of Time Spent in REM Sleep | 21.1 (15.53 to 26.65) |
| Percentage of REM runs | Cognitively Normal (CN) Older Adults |
|---|---|
| Percentage of REM Runs That Are Less Than 5 Minutes | 20 ± 35 |
| Percentage of REM runs | Cognitively Normal (CN) Older Adults |
|---|---|
| Percentage of REM Runs That Are Greater Than or Equal to 5 Minutes | 80 ± 35 |
| Percentage of REM runs | Cognitively Normal (CN) Older Adults |
|---|---|
| Percentage of REM Runs That Are Greater Than or Equal to 10 Minutes | 56.35 ± 43.89 |
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.
| Percentage of correct responses | Cognitively Normal (CN) Older Adults |
|---|---|
| Percentage of Correct Responses on the Picture Test | 90.62 ± 9.38 |
N2 Spindle Density is derived from in-laboratory nocturnal polysomnography (NPSG) sleep study.
| spindles/min | Cognitively Normal (CN) Older Adults |
|---|---|
| Number of Sleep Spindles That Occur Per Minute During the N2 Stage of Sleep (N2 Spindle Density) | 0.23 ± 0.53 |
PVT measures the reaction speed to a randomly time-occuring visual stimuli, allowing the assessment of several aspects of attention including response times, attention lapses and false starts.
| milliseconds | Cognitively Normal (CN) Older Adults |
|---|---|
| Mean Psychomotor Vigilance Test (PVT) Reaction Time | 277.9 ± 42.27 |
The "Picture" test is used to measure the strength of the participants' memory by using a series of images. Before sleep, participants identify whether or not the image was inside or outside and whether or not the picture was emotional or neutral to them. After sleep, the participant will be shown images where some are new and some are old and asked whether or not they saw them before sleep. The images are selected from The International Affective Picture System.
| Seconds | Cognitively Normal (CN) Older Adults |
|---|---|
| Picture Test Response Time | 1.2 ± 1.05 |
Levels will be derived from the plasma and reported in pg/mL
| pg/mL | Cognitively Normal (CN) Older Adults |
|---|---|
| Levels of Hyperphosphorylated Tau (P-Tau) | 0.34 ± 0.15 |
Collected over Adverse events, serious adverse events, and all-cause mortality were assessed only during the course of each participant's active study procedures (home sleep monitoring, in-lab NPSG, PET/MR imaging, and blood collection), with no post-study follow-up period (up to 8 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cognitively Normal (CN) Older Adults | 0/34 (0%) | 0/34 (0%) | 0/34 (0%) |
All participants for which demographic information was collected were included in the demographics analysis.
| Age, Continuous(years) | Cognitively Normal (CN) Older Adults |
|---|---|
| Mean | 62.65 ± 5.1 |
| Sex: Female, Male(Participants) | Cognitively Normal (CN) Older Adults |
|---|---|
| Female | 21 |
| Male | 11 |
| Race (NIH/OMB)(Participants) | Cognitively Normal (CN) Older Adults |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 14 |
| White | 17 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cognitively Normal (CN) Older Adults |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 23 |
| Unknown or Not Reported | 7 |
| Region of Enrollment(participants) | Cognitively Normal (CN) Older Adults |
|---|---|
| United States | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Immediately following publication. No end date.
Access criteria: The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Ran from Aug 2020 to primary completion in Mar 2024, 43 months.
Results were first posted in Nov 2026, 2 years 7 months after primary completion. A results delay was requested in Mar 2025.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 43 months is above that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.